New Research at Ohio State University Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solab Institute (OSUCCC-James) Turn Cancer Scientists into Molecular Detectives to Spread Specific Cancers It evolves by looking for clues as to why it can and studying tissues collected within hours of death.
This unique clinical research study, led by Dr. Sameek Roychowdhury, is known as the Rapid Cancer Research Autopsy Trial and can bring together scientists. Biological sample After the patient’s death, to do research that would otherwise not be possible cancer cell Overcame various treatments.
“As the patient receives Cancer treatmentRoychowdhury, a medical oncologist and researcher at the OSUCCC-James Translational Therapeutics Program, said: A rapid autopsy program allows you to sample all cancer sites in your body. This helps to understand how cancer cells have overcome different treatments and then return to the blueprints to develop better treatments for different genes and types of cancer. increase. “
In this Perotonia-sponsored study, patients have a lifetime consent to provide biological samples at the time of death for the purpose of cancer research. Once the patient has passed, researchers will quickly mobilize and perform an autopsy before the tissue deteriorates. Samples are stored to “freeze / pause” tissue properties at that point, so go back to the lab and explain why the treatment stopped working in the hope of guiding future treatments. You can identify potential genetic mutations or cell characteristics that can occur.
Research Results Affecting Cancer Treatment
Since the start of the trial in 2016, the OSUCCC-James Rapid Research Autopsy Team has performed 55 autopsies. The data collected from these autopsies has already led to new discoveries about the drug resistance mechanism of a recently approved new targeted therapy called infigratinib, which is marketed as Torceltic. The drug targets a mutation in the FGFR2 gene known as a fusion in bile duct cancer and other types of cancer.
The team recently published the findings in a medical journal Lancet: Gastroenterology and Hepatology From a single-arm, multicenter, phase II trial of the drug infigratinib in patients previously treated for locally advanced or metastatic cholangiocarcinoma, a rare and difficult-to-treat form of the bile duct. The results showed a significant effect on tumor response, leading to FDA approval of this treatment for bile duct cancer and these specific FGFR2 fusions in May 2021. Beyond bile duct cancer, OSUCCC-James researchers are enrolling patients in a phase II trial of infigratinib in other patients. Types of cancer with FGFR gene mutations. This study was designed and developed by the OSUCCC-James team as a researcher-led trial in collaboration with the drug development industry. Roychowdhury states that this study may provide evidence that more patients with FGFR gene mutations can benefit from new therapeutic approaches that directly target FGFR.
“This represents a powerful new treatment option for diseases with limited treatment options,” Roy Choudhry said. “We are very humble in the patient’s selflessness by participating in studies that help others. Both precision cancer medicine and research autopsy trials lead to patient bedside discoveries. It’s a legacy of hope and it’s exciting to see. “
Roychowdhury says his team is constantly humbled by the patient’s enthusiasm to help proceed with the study in the best possible way, even if those findings are not in time to eradicate their own illness. increase.
“Everyone on our team considers it a privilege and a duty to take care of them and use them in their research. autopsy To help others as the patient wanted, “he said. cancer, Develop treatments and find better ways to understand biology. But what’s even more rewarding is the fact that almost every family told me how grateful their loved ones were to be part of the study. ”
Milind Javle et al, Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement: mature from multicenter, open-label, single-arm, phase II trials result, Lancet Gastroenterology and Hepatology (2021). DOI: 10.1016 / S2468-1253 (21) 00196-5
Ohio State University
Quote: A “research autopsy” helps scientists study why certain cancer treatments fail (September 28, 2021).
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
‘Research autopsy’ helps scientists study why certain cancer therapies stop working Source link ‘Research autopsy’ helps scientists study why certain cancer therapies stop working
The post ‘Research autopsy’ helps scientists study why certain cancer therapies stop working appeared first on California News Times.